SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 639.75 |
| Enterprise Value ($M) | 715.75 |
| Book Value ($M) | -78.98 |
| Book Value / Share | -0.06 |
| Price / Book | -8.10 |
| NCAV ($M) | -101.65 |
| NCAV / Share | -0.07 |
| Price / NCAV | -6.29 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | n/a |
| Return on Assets (ROA) | -2.93 |
| Return on Equity (ROE) | n/a |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.06 |
| Current Ratio | 0.06 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 4.06 |
| Assets | 26.73 |
| Liabilities | 105.71 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 1.38 |
| Operating Income | -66.51 |
| Net Income | -83.78 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -57.02 |
| Cash from Investing | -1.01 |
| Cash from Financing | 56.78 |
(click for more detail) |
|
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Similar Companies | |
|---|---|
| NUNZ – Nunzia Pharmaceutical Company | NVSEF – Novartis AG |
| NVYTF – Novacyt S.A. | NXEN – Nexien BioPharma, Inc. |
| NYMXF – Nymox Pharmaceutical Corporation |